• About CML-IQ
  • Congresses and Events
  • Have Your Say
  • CML Radio
  • CML Library
  • Contact Us
  • A
  • A
  • A

  • Home
  • Understanding CML
  • Medications
  • Health and Lifestyle
  • Subscribe
CML-IQ > Medications > Treating CML early – a cautionary tale

Treating CML early – a cautionary tale

November 19, 2015
by Kate Stella
TKIs
0 Comment
Print

It’s not always a simple matter to get access to the medications you need, but a delay in starting treatment for CML can jeopardize the success of therapy. This was shown in a recent study conducted in Bosnia, where people often face considerable red tape before they can start a TKI such as Gleevec, Sprycel or Tasigna.

Researchers in that country looked at treatment starts to see if delays had an impact on outcomes (Kurtovic-Kozaric and colleagues. Br J Haematol 2015; epublished November 11, 2015). Overall, two-thirds of people with CML had to wait a median of 14 months before starting therapy. Only 16% started a TKI in the first three months after being diagnosed.

In the group who started Gleevec right away, two-thirds achieved a complete cytogenetic response (CCyR) in the first year, compared to 18% of those who started 6-12 months after diagnosis, and 15% of those who had to wait over a year for treatment. Ten percent of people starting treatment right away achieved a major molecular response (MMR; or a 3-log reduction) in the first year. No one achieved MMR if they didn’t get prompt access to the drug.

Some of the problems of delayed access could be offset by starting a more potent, second-generation drug. Delaying treatment didn’t affect success rates for people taking Tasigna.

 

Share this Article

About the Author
Social Share
  • google-share

subscribe-right

About CML-IQ

CML-IQ is a free information service offering the latest research news on chronic myelogenous leukemia (CML), tips on living with the disease, and practical advice to help in making decisions.

Contact Us

info@CML-IQ.com

Stay connected

facebook-icontwitter-iconpinterest-iconyoutube-icongoogle-plus-icon

subscribe-cmliqnews

Copyright 2016 Lind Publishing Inc All rights reserved.
Site map | Privacy | User Agreement
Developed byIntegration New Media, Inc. (INM)